The landscape of new therapies in multiple myeloma trials is rapidly evolving, with stringent global regulations around blinded independent central review (BICR) for efficacy endpoints.
This webinar will review the challenges of conducting BICR and highlight how clinical trial sponsors can optimize endpoint assessments to meet their development goals. The panel includes Perceptive scientists with expertise in myeloma clinical trials and a globally-renowned myeloma physician with a blended background as a clinician AND an independent reader.
– Imaging and its relevance in the context of response evaluation – Relevance of PET and metabolic response for evaluation under IMWG criteria – Incorporating lesions on physical examination – Evaluating local and central lab datasets for efficacy with emphasis on the confirmation of progression – Suppression of light chains with newer therapies and methods to interpret them for response
"*" indicates required fields
Δ
